临床试验药物安全性 1506条(本栏目收费,不能显示细节,电话15274084725)
Cilloni study,372,374 374
Circulating tumor cells (CTC),405,408 408
HCV infections,646,647 647
Cisplatin,black box warning,694,695 695
Cladribine multiple sclerosis management,620,621 621
Clinical Hold,754,755,810,811 811
FDA’s decision-making process inimposing,811 811
Clinical research associate (CRA),133,530 530
Clinical Study Protocol (CSP) amendments,66,68 68
inclusion/exclusion criteria,84,85 85
ABC transporters,97,98 98
Accelerated approval,806,808,812 813 806,808,812 813
Active control (AC),40,41,43,58,59 59
Acute lymphocytic leukemia (ALL),331 331
clinical features,339,340 340
cytogenetics for diagnosis and prediction,355,358,375 375
minimal residual disease,368,374 374
Acute myeloid leukemia (AML),331 331
clinical features,343,345 345
cytogenetics for diagnosis and prediction,354,355 355
Acute promyelocytic leukemia (APL),345,346,374 374
exemplified by hepatitis C virus,818,820 820